153 related articles for article (PubMed ID: 27713306)
1. Health Economics of Antibiotics.
Simoens S
Pharmaceuticals (Basel); 2010 Apr; 3(5):1348-1359. PubMed ID: 27713306
[TBL] [Abstract][Full Text] [Related]
2. What is the value for money of medicines? A registry study.
Simoens S
J Clin Pharm Ther; 2012 Apr; 37(2):182-6. PubMed ID: 21812796
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
Picavet E; Cassiman D; Simoens S
J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
6. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
7. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):395-420. PubMed ID: 15853438
[TBL] [Abstract][Full Text] [Related]
8. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.
Lin PJ; D'Cruz B; Leech AA; Neumann PJ; Sanon Aigbogun M; Oberdhan D; Lavelle TA
Pharmacoeconomics; 2019 Apr; 37(4):597-608. PubMed ID: 30903567
[TBL] [Abstract][Full Text] [Related]
9. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
11. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation.
Witiw CD; Tetreault LA; Smieliauskas F; Kopjar B; Massicotte EM; Fehlings MG
Spine J; 2017 Jan; 17(1):15-25. PubMed ID: 27793760
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
Vanagas G; Padaiga Z; Mickevičienė A
Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Croom KF; Plosker GL
Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
[TBL] [Abstract][Full Text] [Related]
18. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.
Lee CP; Chertow GM; Zenios SA
Value Health; 2009; 12(1):80-7. PubMed ID: 19911442
[TBL] [Abstract][Full Text] [Related]
19. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.
Hofer F; Kauczor HU; Stargardt T
Lung Cancer; 2018 Oct; 124():189-198. PubMed ID: 30268459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]